DDInter940 DDInter704
Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Insulin lispro {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Insulin lispro {u} may cause a minor interaction that can limit clinical effects when taken with {v} Phentolamine
Phentolamine {u} (Compound) downregulates {v} (Gene) CDC20
CDC20 {u} (Gene) is downregulated by {v} (Compound) Everolimus
Insulin lispro {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Pimecrolimus
Pimecrolimus {u} (Compound) resembles {v} (Compound) Everolimus
Insulin lispro {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lipoic acid
Lipoic acid {u} (Compound) binds {v} (Gene) POR
POR {u} (Gene) is upregulated by {v} (Compound) Everolimus
Insulin lispro {u} may cause a minor interaction that can limit clinical effects when taken with {v} Phentolamine
Phentolamine {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Everolimus
Insulin lispro {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Temsirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Insulin lispro {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Amcinonide {u} (Compound) upregulates {v} (Gene) TIPARP
TIPARP {u} (Gene) is upregulated by {v} (Compound) Everolimus
Insulin lispro {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) binds {v} (Gene) FKBP1A
FKBP1A {u} (Gene) is bound by {v} (Compound) Everolimus
Insulin lispro {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Captopril
Captopril {u} (Compound) upregulates {v} (Gene) RELB
RELB {u} (Gene) is upregulated by {v} (Compound) Everolimus
Insulin lispro {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Benzphetamine
Benzphetamine {u} (Compound) binds {v} (Gene) POR
POR {u} (Gene) is upregulated by {v} (Compound) Everolimus
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)
Insulin lispro may cause a minor interaction that can limit clinical effects when taken with Phentolamine and Phentolamine (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Everolimus (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Pimecrolimus (Compound) and Pimecrolimus (Compound) resembles Everolimus (Compound)
Insulin lispro may cause a minor interaction that can limit clinical effects when taken with Lipoic acid and Lipoic acid (Compound) binds POR (Gene) and POR (Gene) is upregulated by Everolimus (Compound)
Insulin lispro may cause a minor interaction that can limit clinical effects when taken with Phentolamine and Phentolamine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Everolimus (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound) and Temsirolimus (Compound) resembles Everolimus (Compound)
Insulin lispro may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide (Compound) upregulates TIPARP (Gene) and TIPARP (Gene) is upregulated by Everolimus (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) binds FKBP1A (Gene) and FKBP1A (Gene) is bound by Everolimus (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Captopril and Captopril (Compound) upregulates RELB (Gene) and RELB (Gene) is upregulated by Everolimus (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Benzphetamine and Benzphetamine (Compound) binds POR (Gene) and POR (Gene) is upregulated by Everolimus (Compound)